|
- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill
- ALZFORUM | NETWORKING FOR A CURE
A large proteogenomic study identified 49 pQTLs, in either CSF or plasma, linked to cerebral small vessel disease Immune and ECM proteins predominated
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the . . .
Zhang L, Zhang L, Li L, Hölscher C Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease J Parkinsons Dis 2019;9 (1):157-171
- Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction . . .
Rubin R Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA 2024 May 14;331 (18):1519-1521 PubMed
- Therapeutics - ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
- Exenatide - ALZFORUM
The short-acting form of exenatide is administered by twice-daily subcutaneous self-injection; a long-acting preparation is injected just once a week In mice, exenatide readily crossed the blood-brain barrier, while other GLP-1 mimetics liraglutide and semaglutide did not (Salameh et al , 2020)
- Liraglutide - ALZFORUM
Background Liraglutide is an analog of glucagon-like peptide 1 GLP-1 is a hormone that is produced in the gut and activates receptors in the gut, liver, and pancreas to control blood-sugar levels and reduce insulin resistance Liraglutide and related GLP-1 mimetics cause body weight loss and reduce the risk of cardiovascular events, stroke, and dementia in people with diabetes
|
|
|